Skip to content
DataLookout
Menu

ARTISTRY-2NCT06333808

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

StatusActive, Not Recruiting
PhasePhase 3
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 5, 2026 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 28 words
    • Interventions modified
    • Trial arms changed: 2 → 3
    • Secondary endpoints: 7 to 11
    • Site details revised at 12 of 104 sites
    • Publications: details revised at 2 of 2 entries
  2. Minor Secondary endpoints revised (7)v12
  3. Minor Primary completion date changed from estimate of Dec 2025 to Oct 27, 2025v11
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 546 to confirmed 577
    • Site details revised at 104 of 104 sites
    v10
  5. Minor Study sites: 89 to 104v9
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 76 to 89v8
  2. Minor Study sites: 68 to 76v7
  3. Minor Study sites: 58 to 68v6
  4. Minor Study sites: 45 to 58v5
  5. Minor Study sites: 33 to 45v4
  6. Minor Study sites: 7 to 33v3
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 7
    • Start date changed from estimate of Mar 2024 to Mar 25, 2024
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Timeframe: Week 48

Secondary (11)

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm
Show 6 moreShow less
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 96
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 144
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144

Arms and interventions

Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mgExperimental

Participants will switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablets to bictegravir/lenacapavir (BIC/LEN) 75/50 mg FDC tablets + placebo-to-match (PTM) B/F/TAF tablets, administered orally, once daily up to 48 weeks. Participants will also receive a 2-day oral pharmacokinetic (PK) loading dose of LEN 600 mg on Days 1 and 2, in addition to the daily doses of BIC/LEN 75/50 mg and PTM B/F/TAF tablets starting on Day 1. At the end of blinded treatment (EBT) participants will enter the open label (OL) phase and continue to receive BIC/LEN 75 mg/50 mg FDC tablets through at least 48 weeks in the OL phase. At the OL Week 48, participants will be given an option to continue to receive BIC/LEN FDC tablets.

Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mgActive comparator

Participants will continue with their B/F/TAF 50/200/25 mg tablets and start PTM BIC/LEN tablets on Day 1 administered orally, once daily up to 48 weeks. Participants will receive PTM oral LEN PK loading tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2). Participants who complete the EBT will be given an option to enter the OL phase to receive BIC/LEN FDC tablets.

Open-label Phase: BIC/LEN 75/50mgExperimental

Participants from Treatment Group 1 will receive BIC/LEN FDC tablets through at least OL Week 48. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets. Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets. Participants from Treatment Group 2 who enter the OL phase will also receive a 2-day oral loading dose of LEN 600 mg (2 × 300 mg LEN on Day 1 and on Day 2). All participants who enter the OL phase may continue to receive BIC/LEN FDC tablets daily until study drug is available or until Gilead Sciences (Gilead) elects to discontinue the study.

Drugs: Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir

Sites

104 sites in 14 countries

United States 51, Germany 7, Italy 7, Canada 6, Spain 6, United Kingdom 5, South Korea 4, Taiwan 4, Argentina 3, Australia 3, Japan 3, Mexico 2, Puerto Rico 2, Dominican Republic 1